Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019 Download PDF   Dear patients, shareholders, friends, In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®. As the European season unfolds, we report on the back of quarterly financials (released 30 April) which are on track against our own projections. Importantly, our commercial teams and finance staff […]

Download PDF
 
 
Tuesday, 30 April 2019

Appendix 4C

Melbourne, Australia, 30 April 2019 Download PDF   CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 January to 31 March 2019. All figures are rounded and […]

Download PDF
 
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Download PDF   Dear All, On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming a lasting success story in Australian life sciences. It will become a Company serving many […]

Download PDF
 
 

04 April 2019   Download PDF to view presentation

Download PDF
 
 

Melbourne, Australia and Leatherhead, UK, 29 March 2019 Download PDF to read more CLINUVEL PHARMACEUTICALS LTD today announced that it will host national expert meetings in Berlin, Germany, on 29 March and Florence, Italy, on 5 April to evaluate the treatment of erythropoietic protoporphyria (EPP). Clinicians and medical staff from a number of EPP expert […]

Download PDF
 
 
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019 Download PDF   Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead.   FDA REVIEW At the time of print CLINUVEL will find itself within four months of the US Prescription Drug User Fee Act (PDUFA) date, while […]

Download PDF
 
 
Friday, 15 March 2019

UK NICE Meeting Held

Melbourne, Australia, 15 March 2019 Third meeting of Highly Specialised Technology Committee CLINUVEL PHARMACEUTICALS LTD  announced that it had met with the Highly Specialised Technology (HST) Committee of the English National Institute of Health and Care Excellence (NICE) in Manchester on 14 March (Greenwich Mean Time) as part of the ongoing evaluation of CLINUVEL’s drug […]

Download PDF
 
 
Wednesday, 13 March 2019

Change in substantial holding

13 March 2019   Form 604Corporations Act 2001Section 671BNotice of change of interests of substantial holder   Download PDF to read more

Download PDF
 
 
Wednesday, 13 March 2019

Change in substantial holding

13 March 2019   Form 604Corporations Act 2001Section 671BNotice of change of interests of substantial holder   Download PDF to read more

Download PDF
 
 

13 March 2019   Change of Director’s Interest Notice   Download PDF to read more

Download PDF
 
 
Wednesday, 13 March 2019

Appendix 3B

13 March 2019   New issue announcement, application for quotation of additional securities and agreement   Download PDF to read more

Download PDF
 
 
Monday, 04 March 2019

Investor Briefing

4 March 2019 Investor Briefing – Non-Deal Roadshow Download PDF to read more

Download PDF
 
 
Tuesday, 26 February 2019

Appendix 4D Half Yearly Report

Melbourne, Australia, 26 February 2019 CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4D – Half Yearly Report for the period 01 July to 31 December 2018. All figures are rounded and reported in Australian […]

Download PDF
 
 
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. Although it is widely accepted in photodermatology that NB-UVB is not a reliable and effective therapy for vitiligo, […]

Download PDF
 
 
Thursday, 07 February 2019

CLINUVEL Newsletter – February 2019

7 February 2019 Dear patients, shareholders, friends, In this second Communiqué for the year we will delve deeper in the ongoing treatment of erythropoietic protoporphyria (EPP) patients in Europe and look ahead at the expected news flow from the US Food and Drug Administration (FDA) in the coming months. Gradually, we are sharing the contours […]

Download PDF
 
Thursday, 05 December 2019

Appendix 3B

 New issue announcement, application for quotation of additional securities and agreement. 

Download PDF
 
Monday, 02 December 2019

CEO Letter

Dear shareholders, On 8 October 2019, CLINUVEL obtained its first and historic US Food and Drug Administration (FDA) approval, some 39 years since the afamelanotide technology was first discovered in a university laboratory. On this day …

Download PDF
 

Dearest Shareholders, As the incoming Chair of the Company, in short letters I will try to provide you with updates and inform you about our business.[...]

Download PDF
 

 CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair …

Download PDF
 
Thursday, 17 October 2019

CLINUVEL Newsletter

  In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the …

Download PDF
 
Tuesday, 15 October 2019

Chair Letter to Shareholders

  Dear All, In my career in life sciences, I have served on public Boards, was part of the management team that led CSL to its position and oversaw several executive transitions in our beloved Company, first …

Download PDF
 
Tuesday, 20 August 2019

CLINUVEL Newsletter - August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. [...]

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF